Leukemia: all 5,475 studies
Page 4 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.
- Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid LeukemiaRecruitingNCT06225128
- A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLRecruitingNCT06220487Phase 2
- INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic LeukemiaNot yet recruitingNCT06209671Phase 1
- TGRX-814 Chinese Phase I/II in Patients With Hematological MalignanciesRecruitingNCT06206174Phase 1/2
- Off-the-shelf CD123 CAR-NK for R/R AMLRecruitingNCT06201247Early Phase 1
- A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid LeukemiaNot yet recruitingNCT06182592Phase 3
- CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLRecruitingNCT06179524Phase 2
- Role of BMP Pathway in MDS ProgressionNot yet recruitingNCT06175923
- Treatment Protocol for Newky Diagnosed Adult Ph Positive ALLNot yet recruitingNCT06175702
- Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML PatientsEnrolling by invitationNCT06162325
- The Role of NK Cells to Detect Blood Infection in ALL.Not yet recruitingNCT06160115
- Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood LeukemiaRecruitingNCT06155188Not applicable
- CIML NK Cells With Venetoclax for AMLRecruitingNCT06152809Phase 1
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationRecruitingNCT06138587Phase 1
- AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaRecruitingNCT06137118Phase 1/2
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT06131801
- Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted TherapyRecruitingNCT06130787Not applicable
- Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)RecruitingNCT06125652Phase 1/2
- Ponatinib in Chronic Myeloid Leukemia Patients in Chronic PhaseRecruitingNCT06119269
- Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06118788Phase 1/2
- Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALLRecruitingNCT06111625Phase 2
- Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementRecruitingNCT06111612
- Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AMLRecruitingNCT06105658Phase 2
- CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and LymphomaRecruitingNCT06101381Phase 1/2
- Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease ProgressionNot yet recruitingNCT06084923
- Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic LeukemiaRecruitingNCT06082934Phase 1/2
- CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic LeukemiaRecruitingNCT06081478Phase 2
- CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).RecruitingNCT06078306Phase 2
- A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06076226
- Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCTNot yet recruitingNCT06075238Phase 2
- A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid LeukemiaRecruitingNCT06073769
- Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCTRecruitingNCT06061094Phase 2
- Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineRecruitingNCT06060782Phase 1
- Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study AnalysisRecruitingNCT06058858
- Shwachman Diamond Syndrome Registry and StudyRecruitingNCT06056908
- QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06056752Phase 1
- Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDSNot yet recruitingNCT06050941Phase 2
- Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDSRecruitingNCT06046313Phase 2
- Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)RecruitingNCT06045819
- To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCLRecruitingNCT06045091Early Phase 1
- Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic LeukemiaRecruitingNCT06034561Phase 2
- Study of VIP943 in Subjects With Advanced CD123+ Hematologic MalignanciesRecruitingNCT06034275Phase 1
- Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INORecruitingNCT06025682
- MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic StrategiesNot yet recruitingNCT06022341Not applicable
- Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)RecruitingNCT06022328
- Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.RecruitingNCT06022016Not applicable
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06001788Phase 1
- Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid MalignanciesRecruitingNCT05991908Phase 3
- Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid LeukemiaEnrolling by invitationNCT05983172
- Acute Myeloid Leukemia RegistryRecruitingNCT05979675
- Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMMLRecruitingNCT05970822Phase 1
- Clonal Hematopoiesis of Immunological SignificanceNot yet recruitingNCT05969821
- Chronic Myeloid Leukemia (CML) Real-Life DatabaseRecruitingNCT05963061
- Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in BrazilRecruitingNCT05959720
- A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .RecruitingNCT05959694Phase 1/2
- A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLLRecruitingNCT05950997Not applicable
- Effect of Supplementation With ω-3 Fatty Acids, Vitamin D and Calcium in Patients With Acute Lymphoblastic Leukemia.RecruitingNCT05950204Not applicable
- Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid LeukemiaNot yet recruitingNCT05944211Phase 2
- H19 in Acute Lymphoblastic Leukemia.Not yet recruitingNCT05943093
- Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell LeukemiaRecruitingNCT05941156Phase 2
- PET Tracer Based FDG Signal for Predicting Prognosis in Acute Myeloid LeukemiaEnrolling by invitationNCT05919199
- Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid LeukemiaRecruitingNCT05918198Phase 2
- Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete RemissionRecruitingNCT05909293Not applicable
- Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic SyndromeRecruitingNCT05902416
- Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia PatientsNot yet recruitingNCT05899543
- Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05893693Not applicable
- A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)Not yet recruitingNCT05876832Phase 3
- A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction FailureNot yet recruitingNCT05875649
- Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi LeukemiaRecruitingNCT05870995Phase 2
- Safety Evaluation Study for Patients With Aggressive NK-cell LeukemiaRecruitingNCT05863234Phase 1/2
- Assessing Medical Trial Experiences of Hairy Cell Leukemia PatientsNot yet recruitingNCT05859932
- I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm PatientsRecruitingNCT05842603Not applicable
- Optimum Induction Therapy of Low-risk APLRecruitingNCT05832320Not applicable
- Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCTRecruitingNCT05823714Phase 2
- CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05822037Not applicable
- Genetic Polymorphisms in Drug Induced Neuropathy in Children With ALLRecruitingNCT05811910
- Mercaptopurine Therapeutic Drug Monitoring to Optimize the Maintenance Phase of Childhood ALLRecruitingNCT05811845
- Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCTRecruitingNCT05809167Phase 2
- Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid LeukemiaRecruitingNCT05807347Phase 2
- Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLRecruitingNCT05805098Phase 2/3
- Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) PatientsNot yet recruitingNCT05805072Not applicable
- Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.RecruitingNCT05803395
- MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingRecruitingNCT05794880Not applicable
- Study of the Impact of Frequency of Changing PICCline Dressings in Patients With Acute LeukemiaRecruitingNCT05793801Not applicable
- Frequency and Risk Factors of Acute Myeloid LeukemiaNot yet recruitingNCT05787951
- Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction StudiesRecruitingNCT05772559
- A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05759793Phase 1
- HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05751044Phase 1/2
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLRecruitingNCT05748171Phase 2
- HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05745714Phase 1/2
- Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareRecruitingNCT05745285Not applicable
- Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic LymphomaRecruitingNCT05745181Phase 2
- Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCTRecruitingNCT05744440Early Phase 1
- Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic MalignanciesRecruitingNCT05739227Early Phase 1
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLRecruitingNCT05735184Phase 1
- UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05731219Phase 1
- Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic LeukemiasRecruitingNCT05729178
- CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic LeukemiaRecruitingNCT05727683Phase 1
- Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT05726110Phase 3
- Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAMRecruitingNCT05697510Phase 1